Abiopharma

Johnson & Johnson - New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

Zai Lab Announces Participation in Investor Conferences in September 2025

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Changes in Interest of Director

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Changes in Interest of Director

Employee Stock Option/ Share Scheme: Lapse of Awards under Share Grant Plan

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas

Windows Security Not Opening: Repair Guide

What To Do If Logitech G Hub Is Not Opening